Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.39 USD | 0.00% | -17.63% | -56.37% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.57 times its sales.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-56.37% | 345M | C+ | ||
-5.56% | 181B | C+ | ||
-0.11% | 108B | C | ||
-6.17% | 66.12B | A | ||
+2.64% | 50.65B | B- | ||
+6.58% | 43.11B | B- | ||
+3.40% | 41.3B | B+ | ||
+21.98% | 31.6B | B | ||
+16.81% | 25.03B | A- | ||
-5.81% | 24.16B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NVRO Stock
- Ratings Nevro Corp.